Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (11360)	8/18/1999 12:45:00 AM
From: Bluegreen	Read Replies (2) \| Respond to of 17367

Tharos, the FDA prefers information to be released at scientific presentations. I'm sure Xoma can say what ever they want at anytime BUT is it prudent and smart? One last thing I will also ask WHAT REGULATORY AGENCY PROOF READ XOMA'S PRESS RELEASE BEFORE IT WAS SENT OVER THE WIRES? This is just a sample of what you can find out IF you are willing to spend some time talking to the company. There are SO many things that go with this being the FIRST or nearly the FIRST BIOLOGICAL before the FDA with subpart E designation. My opinion is DON'T go by past or compare apples to oranges.....we are actually seeing history being made with this drug and its approach toward FDA approval. DON'T assume anything in this process, if you have questions just ask XOMA.

To: Tharos who wrote (11360)	8/18/1999 1:08:00 AM
From: dwight martin	Respond to of 17367

be more prepared for the type of people that seem to be able to get press passes. Yeah, ever since the press-assisted Nixon denoument, the field has been overrun by !gotcha! types whose mission, mounted under the banner of Truth, is to advance their careers by exposing every public person as a liar, or making them look like one. Pity is, Americans lap that stuff up! Still, this doesn't fully excuse lack of precautions by XOMA IR against being misquoted, and the lack of a strong counterpunch. What are the odds it'll boil down to a swearing contest? I sent a critical (mebbe even mean) E-Mail to Bloomberg (they have cleverly hidden their contact info under the "HELP" button) about the remaining variation between what their latest update claims and what XOMA says. They say they will get back within 24 hours. I will be VERY impressed if they even respond, but I'm not holding my breath.

To: Tharos who wrote (11360)	8/18/1999 1:25:00 AM
From: aknahow	Respond to of 17367

I have been down this path and I believe I was incorrect in my assumptions. When did the trial you reference conclude? Were the results published anywhere else prior to the referenced release? Do you think it is different to release information at the time of submission than while the data is still being analyzed? Do you think it makes any difference if a company has already run several P III trials and is now releasing data on the third or fourth P III trial than releasing data on a pivotal P III trial?